Ignite Creation Date:
2024-05-05 @ 4:38 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00285025
Status:
COMPLETED
Last Update Posted:
2006-02-01
First Post:
2006-01-31
Brief Title:
Study of the Effect of SR57667B in Patients With Alzheimers Disease
Sponsor:
Sanofi
Organization:
Sanofi
Study Overview
Official Title:
A Phase II Multicenter Multinational Randomized Double-Blind Placebo-Controlled Efficacy Safety and Tolerability Study of SR57667B in Patients With Mild-to-Moderate Alzheimers Disease
Status:
COMPLETED
Status Verified Date:
2006-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective is to demonstrate that SR57667B at the dose of 4 mgday in comparison to placebo decreases the decline in cognitive performance and the global clinical decline over 1 year in patients with mild to moderate AD
Secondary objectives are to assess the effect of SR57667B on functional decline and its safetytolerability in patients with mild to moderate AD and to document plasma concentrations of SR57667 in patients with mild to moderate AD
Secondary objectives are to assess the effect of SR57667B on functional decline and its safetytolerability in patients with mild to moderate AD and to document plasma concentrations of SR57667 in patients with mild to moderate AD
Detailed Description:
Multinational multicenter randomized parallel-group double-blind phase II study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| SR57667B | None | None | None |